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Abstract
Background: Traditional cardiovascular risk factors in the general population are usually correlated to a better
prognosis in patients with chronic heart failure (HF). Most of the studies show that blood pressure variability (BPV)
has noxious effect on general population but data are missing for patients with systolic HF. The aim of this study
was to assess the prognostic impact of short-term blood pressure variability (BPV) in systolic HF.
Methods and results: We retrospectively studied 288 patients (60 ± 12 years-old; 79 % male) referred to our
tertiary center of HF for the management of their systolic HF (left ventricular ejection fraction was 28 ± 9 %). All
patients underwent ambulatory blood pressure monitoring (systolic BP: 110 ± 15; diastolic BP: 68 ± 10 and pulse
pressure: 42 ± 11 mmHg) and the prognostic impact of BPV was collected with a mean follow-up of 4.4 ± 3.1 years.
Twenty-five (9 %) patients were missing for follow-up. Among the others patients, 70 (27 %) cardiovascular events
(cardiac deaths: 24 %; heart transplantation: 2 %) were recorded. By multivariate analysis BPV daytime (OR = 0.963,
p = 0.033) and severe NYHA class (OR = 5.2, p < 0.0001) were found as independent predictors of cardiac event.
Patients with a systolic daytime BPV under a cut-off value of 19 mmHg had the poorest prognosis with an OR for
cumulative events of 1.65 (IC95 % 1.1–2.7; p < 0.04).
Conclusion: BPV is simple tool and a predictor of cardiac events in patients with systolic HF.
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Background
If high blood pressure (BP), body mass index and choles-
terolemia represent traditional cardiovascular risk fac-
tors in the general population, they are correlated to a
better prognosis in patients with chronic heart failure
(HF) [1–3]. In a meta-analysis, Raphael and al empha-
sized the paradoxical effect of higher systolic BP on mor-
tality of patients with chronic HF, showing a decrease of
13 % in cardiovascular death for an increase of 10 mmHg
in systolic BP [1]. For the last decades, the prognostic
impact of each determinant of BP profile such as systolic
BP, diastolic BP, pulse pressure (PP), BP variability (BPV)
was essentially studied in patients with hypertension [4],
but few in chronic HF. Thus, Rothwell et al. showed in a
hypertensive population that the daytime BPV was a
powerful predictor of stroke and coronary events [5].
The aim of the present study was to assess the prognos-
tic impact of short-term BPV in chronic systolic HF.
Method
Population
Patients were retrospectively extracted from our local
database of HF and including patients referred the ex-
ploration and the management of systolic HF in of
the HF unit of the University Hospital of Toulouse
from 1999 to 2006. Inclusion criterions were: age over
18 years old, one systolic HF event in life, systolic
dysfunction defined by left ventricular ejection frac-
tion <45 %, ambulatory monitoring of BP in at admission.
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Exclusion criterions were: patients with low flow or
treated with intravenous drugs such as inotropic support,
infection, dialysis and incomplete ambulatory monitoring
of BP.
The study was approved by our local ethics committee.
Twenty-four-hour ABPM
Twenty-four-hour ambulatory BP monitoring (ABPM)
was performed as previous described in chronic HF
[6], using the oscillometric method (Spacelabs 90207
device® [7]). Successive BP measures were performed
every 15 min during daytime (7 am. to 9:59 pm.) and
every 30 min during nighttime (10 pm. to 6:59 am.).
BP measures were expressed in millimetres of mer-
cury (mmHg). All devices for ABPM were placed on
the right arms by a trained nurse 24-h after admis-
sion. Patients were instructed to relax the cuffed arm
during the measure and received a diary to record
unexpected events. The analysis of ABPM records
were performed using Spacelabs software allowing us
to extract systolic BP, diastolic BP, PP, BPV and Dip
ratio daytime and nighttime BPV was calculated using
the average difference between maxima and minima
from each systolic BP measure to another. Nighttime
BP dipping can be quantified as the ratio of mean
nighttime (sleep) BP to mean daytime (awake) BP.
The calculation formula was: BPV = (maximum systolic
BP – minimum systolic BP)/2.
Follow-up
Follow up was conducted using physician, patient or
family phone contacts. Patients without news within the
last month after the AMBP were considered as missing
for follow-up. The composite endpoint was defined by
the occurrence of cardiovascular events: cardiac death or
heart transplantation.
Statistical analysis
Continuous variables with a normal distribution are
expressed as mean ± standard deviation (SD). To com-
pare numerical data between two groups, paired and
unpaired Student t-test was used when appropriate.
Nominal variables were compared using either the χ2
or Fischer tests when appropriate. Univariate analysis
of the predictive factors of cardiovascular event was
performed using respectively log rank and cox methods
for qualitative and quantitative variables. Kaplan Meier
curve and log mantel cox method were used to illus-
trate prognosis of high and low level of systolic BP
and VBP. Variables from the univariate analysis with
P < 0.1 were included in the multivariable stepwise
analysis to identify independent predictors of events.




Two hundred and eighty eight patients (mean age
60 ± 12, 79 % male) with systolic HF were included
in the study. The baseline characteristics are summa-
rized in Table 1. Mean left ventricular ejection fraction
was 28 ± 9 %. One hundred and thirty one (45 %) patients
had ischemic cardiomyopathy, 123 (43 %) patients had
primitive dilated cardiomyopathy, 37 (13 %) patients
suffered from an alcohol-abused cardiomyopathy and 13
(5 %) patients had valvular heart diseases. There were 16
(6 %), 137 (47 %), 122 (42 %) and 13 (5 %) patients with
NYHA stage I, II, III and IV, respectively.
The usable of BP records during the 24-h monitoring
was 87 ± 11 %. Regarding BP profile, mean systolic BP was
110 ± 15 mmHg, mean diastolic BP was 68 ± 10 mmHg
and PP was 42 ± 11 mmHg during the 24-h monitoring.
Mean BPV was higher on daytime versus nighttime
(23 ± 9 vs. 18 ± 7 mmHg, p < 0.0001, respectively). De-
tails of ABPM are shown in Table 2.
Follow-up and events
Twenty-five (9 %) patients were missing for follow-up.
Among the 263 others patients, 70 (27 %) cardiovascu-
lar events were recorded including 64 (24 %) cardiac
deaths and 6 (2 %) heart transplantations with a mean
follow up of 4.4 ± 3.1 years. The event group display a
worse functional state (74 % vs. 38 %, p < 0.0001 for
NYHA III/IV) with more often decompensate HF at
Table 1 Baselines characteristics
N 288
Age, years 60 ± 12
Female, n (%) 61 (21)
BMI, Kg/m2 26 ± 4





Left Ventricular Ejection Fraction, % 28 ± 9
Hypertension, n (%) 125 (43)
Diabetes, n (%) 61 (21)
Ischemic cardiomyopathy, n (%) 131 (45)
Primitive cardiomyopathy, n (%) 123 (43)
Valvular cardiomyopathy, n (%) 13 (5)
Congestive heart failure, n (%) 123 (42)
ACE inhibitors, n (%) 239 (83)
Beta-Blockers, n (%) 179 (62)
Spironolactone, n (%) 141 (49)
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admission (55 % vs. 38 %, p = 0.016) than the non-event
group. This increase of congestive signs in the event
group led to an increased of diuretics administration in
comparison with to the non-event group (95 vs. 83 %,
p = 0.013). However, there was no significant differ-
ence for left ventricular ejection fraction between the
two groups (p = 0.19).
There was no difference for BP profile between pa-
tients with event and patients without event, except
for daytime systolic BP (108 ± 16 vs. 113 ± 15 mmHg,
p = 0.03, respectively), daytime diastolic BP (68 ± 9 vs.
71 ± 10 mmHg, p < 0.05, respectively) and daytime
BPV (22 ± 6 vs. 24 ± 9 mmHg, p < 0.05, respectively).
Results according to the occurrence of events are
shown in Table 3.
Univariate predictors of cardiac event
Results of univariate analysis are summarized in Table 4.
By univariate analysis, discriminative-predictive vari-
ables were NYHA stage III/IV (OR = 5.1, IC95 %: 3–8,
p < 0.0001), LVEF < 25 %(OR = 1.96, IC95 %: 1.1–3.6,
p = 0.01), congestive CHF (OR = 2.15, IC95 %: 1.3–3.5,
p < 0 .002), decrease of natremia (1 mM/L;OR = 0.93,
IC95 %: 0.870–0.990, p = 0.03), increase of the clear-
ance of creatininemia (1 mL/min; OR = 0.988, IC95 %:
0.979–0.997, p = 0.01).
Regarding the BP profile, each 1 mmHg increase of 24-h
systolic BP (OR = 0.979, IC95 %:0.962–0.996, p < 0.02),
daytime systolic BP (OR = 0.977, IC95 %: 0.961–0.994,
p < 0.01), nighttime systolic BP (OR = 0.984, IC95 %:
0.969–1, p < 0.05) daytime diastolic BP (OR = 0.982,
IC95 %: 0946–0.998, p < 0.04) and systolic BPV (OR =
0.958, IC95 %: 0.924–0.993, p = 0.02) were correlated
with a decrease of cardiac events. PP and systolic Dip
had not significant impact in prognosis (Table 4B.)
The Fig. 1 illustrates the predictive positive impact of
a daytime SBP ≤ 110 mmHg on cumulative survival.
Multivariate analysis
Daytime BPV, daytime SBP, nighttime SBP, daytime and
nighttime PP for ABPM variables, and age, body mass
index, diabetes and decompensate HF for clinical vari-
ables were included in stepwise multivariable cox model.
Forward and backward stepwise allowed to characterize
BPV daytime (OR = 0.963, p = 0.033) and severe NYHA
class (OR = 5.2, p < 0.0001) as two independent predic-
tors of cardiac events. As shown in Fig. 2, a systolic day-
time BPV under a cut-off value of 19 mmHg had a poor
prognostic impact with an OR for cumulative events of
Table 2 ABPM among the overall population’s study
ABPM 24 h Daytime Nighttime
SBP, mmHg 110 ± 15 112 ± 16 107 ± 16
DBP, mmHg 68 ± 10 70 ± 10 65 ± 10
PP, mmHg 42 ± 11 42 ± 11 42 ± 11
BPV, mmHg 21 ± 7 23 ± 9 18 ± 7
Dip, mmHg - - -6,6 ± 8
BPV blood pressure variability, DBP diastolic blood pressure, PP pulse pressure
Table 3 Events (cardiac death or heart transplantation)
according to baseline characteristics (A) and blood pressure
profile (B)
A.
Baseline characteristics Event (n = 70) No event (n = 218) p
Age, years 62 ± 12 59 ± 12 0.1
Male, n (%) 60 (86) 167 (77) 0.1
BMI 25.2 ± 3.6 26.2 ± 5.8 0.03
NYHA I &II, n (%) 18 (26) 135 (62) <0.001
NYHA III&IV, n (%) 52 (74) 83 (38)
LVEF, % 27 ± 10 29 ± 9 0.2
Congestive HF, n (%) 39 (55) 83 (38) <0.05
Diabetes, n (%) 19 (27) 42 (19) 0.16
Hypertension, n (%) 22 (31) 103 (47) 0.02
Ischemic, n (%) 34 (49) 97 (44) 0.5
Cockcroft, ml/min 64 ± 24 72 ± 28 <0.05
Heart rate, bpm 79 ± 15 79 ± 18 0.8
ACE inhibitor, n (%) 54 (77) 187 (86) 0.09
ARA2, n (%) 7 (10) 12 (6) 0.19
Spironolactone, n (%) 34 (49) 106 (49) 0.99
B-blockers, n (%) 38 (54) 141 (65) 0.12
Ca-channel blockers, n (%) 1 (1) 12 (6) 0.15
Nitride, n (%) 12 (17) 43 (20) 0.6
Diuretics, n (%) 66 (94) 182 (83) 0.02
B.
Blood pressure profile Event (n = 70) No event (n = 218) p
SBP 24-h, mmHg 107 ± 15 111 ± 15 0.05
SBP daytime, mmHg 108 ± 16 113 ± 15 0.03
SBP nighttime, mmHg 104 ± 15 108 ± 17 0.13
DBP 24-h, mmHg 66 ± 9 69 ± 9 0.06
DBP daytime, mmHg 68 ± 9 71 ± 10 <0.05
DBP nighttime, mmHg 64 ± 10 66 ± 11 0.24
DIP, mmHg 3.4 ± 5 4.5 ± 7 0.23
PP daytime, mmHg 40 ± 11 42 ± 10 0.13
PP nighttime, mmHg 40 ± 11 42 ± 11 0.22
BPV daytime, mmHg 22 ± 6 24 ± 9 <0.05
BPV nighttime, mmHg 17 ± 6 18 ± 8 0.4
ACE angiotensin converting enzyme, ARA2 angiotensin 2 receptor antagonist,
BMI body mass index, LVEF left ventricular ejection fraction, NYHA New York
Heart Association, BPV blood pressure variability, DBP diastolic blood pressure,
PP pulse pressure
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1.65 (IC95 % 1.1–2.7; p < 0.04). The association of
NYHA and BPV gave a better prognosis (Fig. 3).
Discussion
Low daytime BPV (<19 mmHg) is found as an independ-
ent factor of cardiac death and/or cardiac transplantation.
The daytime level of BPV, as systolic BP level, is correlated
with the prognosis of patients with systolic HF. Previous
study of Gibelin et al. [8] showed a worse prognosis of a
low BPV in 154 patients with CHF. Our study confirms
this result with a biggest recruitment during a mean
follow up of 4.4 years. Thus, in comparison to previous
studies on the prognostic value of BPV in hypertension,
we have demonstrated a paradoxical prognostic impact of
BP variability on cardiovascular event occurrence in
systolic HF (cardiac death and heart transplantation).
Determinant factors of BPV in CHF
Decrease of BPV in patients with CHF is well described.
Radaelli et al. [9] demonstrated an alteration of BPV in
nine patients with congestive CHF during exercise with
a BPV of 15 and 41 mmHg2 in patients with CHF and
healthy control subjects respectively [2]. The question
that remained is: what mechanism(s) underlie(s) the de-
crease of BPV in CHF? If components involved in BP as
cardiac output or systemic vascular resistance are well
identified in patients with CHF, determinant factors of
its variability are unclear. Intrinsic factors such as
baroreflex sensibility [10], autonomic nervous system in-
tegrity [11], pre-load volume, myocardial contractile re-
serve, circadian hormonal secretion [12] are potential
pathways that could participate to BPV. Also, extrinsic
factors such as daily activities, stress and smoking must
Table 4 Univariate analysis for cardiac events (cardiac death or
heart transplantation)
A.
Baseline characteristics OR IC95 % p
Age 1.016 0.997–1.036 0.12
Male 0.644 0.33–1.259 0.19
BMI 0.954 0.903–1.007 0.09
NYHA III -IV 5.1 3–8.8 <0.0001
LVEF <25 % 1.959 1.073–3.575 0.01
Congestive 2.15 1.34–3.45 <0.002
Diabetes 0.65 0.38–1.1 0.08
Hypertension 0.493 0.297–0.817 0.005
Ischemic cardiomyopathy 0.859 0.538–1.373 0.5
Cockcroft ml.min¯1 0.988 0.979–0.997 0.01
Heart rate 0.999 0.984–1.014 0.9
B.
Blood pressure profile OR IC95 % p
SBP 24 h 0.979 0.962–0.996 <0.02
SBP daytime 0.977 0.961–0.994 <0.01
SBP nighttime 0.984 0.969–1 <0.05
DBP 24 h 0.974 0.948–1 0.05
DBP daytime 0.982 0.946–0.998 <0.04
DBP nighttime 0.985 0.962–1.008 0.2
DIP Systolic 0.987 0.955–1.02 0.4
DIP Diastolic 0.987 0.961–1.015 0.4
PP daytime 0.975 0.951–1 0.052
PP nighttime 0.978 0.955–1.002 0.07
Systolic BPV daytime 0.958 0.924–0.993 0.02
Systolic BPV nighttime 0.975 0.938–1.013 0.19
BMI body mass index, LVEF left ventricular ejection fraction, NYHA, New York
Heart Association, BPV blood pressure variability, DBP diastolic blood pressure,
PP pulse pressure
Fig. 1 Mean daytime systolic blood pressure level and survival. This
figure shows the impact of daytime systolic blood pressure level
with a cut-off value of 110 mmHg on survival in patients with
systolic heart failure
Fig. 2 Blood pressure variability group patient. This figure shows the
impact of blood pressure variability with a cut-off value of 19 mmHg
on survival in patients with systolic heart failure
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probably participate to BPV in patients with systolic
CHF.
Paradoxical prognostic of BPV: one more Paradigm
in CHF
For the last three decades, several studies demonstrated
that usual cardiovascular risk factors become good prog-
nosis markers in patients with CHF. Thus, high body
mass index [13], hypercholesterolemia or high BP are as-
sociated with survival in a CHF population [14]. If BPV
is added to lots of complex physiological adaptive system
to survive [10], a high level of it worse the prognostic of
hypertensive patients [15] whereas a very low level worse
the prognosis of CHF. That is one more paradigm in
CHF and BPV must be took into account among the
reverse epidemiology of conventional risk factors in
CHF [16].
Conclusion
BPV is simple tool, easily available, predictor of cardiac
death and/or cardiac transplantation in patients with
systolic HF. Measure of BPV could help physicians to
improve the management of patients with HF by
helping to better assess the prognosis and adjust the
therapeutics.
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